Akari Logo (1).jpg
Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference
May 26, 2016 07:00 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
Akari Logo (1).jpg
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome
May 23, 2016 07:10 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Logo (1).jpg
Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
May 19, 2016 07:30 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin...
Achillion-Logo-150 (4).jpg
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
May 19, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN,...
Achillion-Logo-150 (4).jpg
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
May 03, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
-  Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...
Akari Logo (1).jpg
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
March 31, 2016 16:03 ET | Akari Therapeutics Plc
NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...
Achillion-Logo-150 (4).jpg
Achillion Reports 2015 Fourth Quarter and Year-End Financial Results
February 25, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve month periods ending December 31, 2015. ...
Achillion-Logo-150 (4).jpg
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
February 11, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
Achillion-Logo-150 (4).jpg
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
February 03, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq.,...
Achillion-Logo-150 (4).jpg
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET | Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...